Omnipod 5 DEXG7G6 pods (GEN 5) 5S
Ended Awarded
- Contract number
- SPE2DR26FY9M0
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,498
Award facts
- Contract value 100% obligated
- $12,497.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $12,497.50 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded contract, with no set-aside designation, was executed on November 3, 2025, with an ultimate completion date of November 4, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement extending through December 2026 that authorizes AmerisourceBergen to supply comprehensive pharmaceutical products and medical supplies across multiple therapeutic domains in support of military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor supplying medications, medical devices, vaccines, and specialized healthcare commodities to defense and veteran healthcare systems. The company's extensive portfolio of competitively awarded federal contracts demonstrates its capability to meet DLA procurement requirements across varying transaction values. This specific delivery order for insulin infusion system pods supports the medical supply needs of military personnel and beneficiaries within DLA's global supply chain network, consistent with the company's established role as a primary pharmaceutical vendor for the Department of Defense.
Quick answers
Who was awarded contract SPE2DR26FY9M0?
SPE2DR26FY9M0 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DR26FY9M0 worth?
The government has obligated $12,498 on SPE2DR26FY9M0.
Is contract SPE2DR26FY9M0 an order under another contract?
Yes. SPE2DR26FY9M0 is a delivery order under SPE2DR25D2018, an indefinite delivery contract.
Was contract SPE2DR26FY9M0 competed?
The extent of competition for SPE2DR26FY9M0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award